News headlines about Nexvet Biopharma plc (NASDAQ:NVET) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nexvet Biopharma plc earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 43.8149159912409 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of Nexvet Biopharma plc (NASDAQ NVET) opened at 6.72 on Friday. Nexvet Biopharma plc has a 52 week low of $2.75 and a 52 week high of $6.76.

TRADEMARK VIOLATION NOTICE: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at

Nexvet Biopharma plc Company Profile

Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal’s immune system, a property referred to as 100% species-specificity.

Insider Buying and Selling by Quarter for Nexvet Biopharma plc (NASDAQ:NVET)

Receive News & Stock Ratings for Nexvet Biopharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexvet Biopharma plc and related stocks with our FREE daily email newsletter.